322 related articles for article (PubMed ID: 32674976)
1. Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer.
Emmett L
Semin Oncol Nurs; 2020 Aug; 36(4):151052. PubMed ID: 32674976
[TBL] [Abstract][Full Text] [Related]
2. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
3. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
Plichta KA; Graves SA; Buatti JM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
[TBL] [Abstract][Full Text] [Related]
4. The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.
Miyahira AK; Soule HR
J Nucl Med; 2022 Mar; 63(3):331-338. PubMed ID: 34675109
[TBL] [Abstract][Full Text] [Related]
5. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.
Chatalic KL; Heskamp S; Konijnenberg M; Molkenboer-Kuenen JD; Franssen GM; Clahsen-van Groningen MC; Schottelius M; Wester HJ; van Weerden WM; Boerman OC; de Jong M
Theranostics; 2016; 6(6):849-61. PubMed ID: 27162555
[TBL] [Abstract][Full Text] [Related]
6. PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?
Sallam M; Nguyen NT; Sainsbury F; Kimizuka N; Muyldermans S; Benešová-Schäfer M
Theranostics; 2024; 14(8):3043-3079. PubMed ID: 38855174
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen theranostics: therapy with lutetium-177.
Ferdinandus J; Violet J; Sandhu S; Hofman MS
Curr Opin Urol; 2018 Mar; 28(2):197-204. PubMed ID: 29278583
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
9. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
10. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
Miyahira AK; Pienta KJ; Babich JW; Bander NH; Calais J; Choyke P; Hofman MS; Larson SM; Lin FI; Morris MJ; Pomper MG; Sandhu S; Scher HI; Tagawa ST; Williams S; Soule HR
Prostate; 2020 Nov; 80(15):1273-1296. PubMed ID: 32865839
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
12. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.
Iravani A; Violet J; Azad A; Hofman MS
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):38-52. PubMed ID: 31595044
[TBL] [Abstract][Full Text] [Related]
13. Prostate Cancer Theranostics: PSMA Targeted Therapy.
Seifert R; Alberts IL; Afshar-Oromieh A; Rahbar K
PET Clin; 2021 Jul; 16(3):391-396. PubMed ID: 34053583
[TBL] [Abstract][Full Text] [Related]
14. PSMA ligands in prostate cancer - Probe optimization and theranostic applications.
Lütje S; Slavik R; Fendler W; Herrmann K; Eiber M
Methods; 2017 Nov; 130():42-50. PubMed ID: 28666778
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific membrane antigen as a target for cancer imaging and therapy.
Kiess AP; Banerjee SR; Mease RC; Rowe SP; Rao A; Foss CA; Chen Y; Yang X; Cho SY; Nimmagadda S; Pomper MG
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):241-68. PubMed ID: 26213140
[TBL] [Abstract][Full Text] [Related]
16. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
18. Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
Miyahira AK; Pienta KJ; Morris MJ; Bander NH; Baum RP; Fendler WP; Goeckeler W; Gorin MA; Hennekes H; Pomper MG; Sartor O; Tagawa ST; Williams S; Soule HR
Prostate; 2018 Aug; 78(11):775-789. PubMed ID: 29717499
[TBL] [Abstract][Full Text] [Related]
19. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
20. Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.
Kumar A; Mastren T; Wang B; Hsieh JT; Hao G; Sun X
Bioconjug Chem; 2016 Jul; 27(7):1681-9. PubMed ID: 27248781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
